Document is current
Any future updates will be listed below
-
Authors
Reid, Tony R
Oronsky, Bryan https://orcid.org/0000-0002-3940-6329
Williams, Jeannie
Caroen, Scott
Conley, Anthony
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04673942 at ClinicalTrials.govnct04673942 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
https://doi.org/10.1200/jco.2024.42.16_suppl.2506
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
https://doi.org/10.1136/jitc-2024-009613
Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing
https://doi.org/10.1136/jitc-2024-008809
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001<sup>TGF-ß Trap</sup>.
https://doi.org/10.1200/jco.2023.41.16_suppl.2550
663 AdAPT-001, a first-in-class 2-in-1 TGF-beta inhibitor plus a checkpoint inhibitor: updated results from a phase 2 study in solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0663
1523 AdAPT-001 in advanced soft-tissue sarcoma (BETA PRIME): a multicenter, open-label, phase 1 clinical trial
https://doi.org/10.1136/jitc-2023-sitc2023.1523
Documents that mention this clinical trial
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
https://doi.org/10.1200/jco.2024.42.16_suppl.2506
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
https://doi.org/10.1136/jitc-2024-009613
Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing
https://doi.org/10.1136/jitc-2024-008809
Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001<sup>TGF-ß Trap</sup>.
https://doi.org/10.1200/jco.2023.41.16_suppl.2550
663 AdAPT-001, a first-in-class 2-in-1 TGF-beta inhibitor plus a checkpoint inhibitor: updated results from a phase 2 study in solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0663
1523 AdAPT-001 in advanced soft-tissue sarcoma (BETA PRIME): a multicenter, open-label, phase 1 clinical trial
https://doi.org/10.1136/jitc-2023-sitc2023.1523
-
Funding
Funding for this research was provided by:
EpicentRx (N/A)
- License Information
